- Title: An outbreak of SARS-CoV-2 in a public-facing office in England, 2021.
- 2 **Authors:** Barry Atkinson<sup>1a\*</sup>, Karin van Veldhoven<sup>2a</sup>, Ian Nicholls<sup>1</sup>, Matthew
- Coldwell<sup>3</sup>, Adam Clarke<sup>3</sup>, Gillian Frost<sup>3</sup>, Christina J. Atchison<sup>4</sup>, Amber I. Raja<sup>5</sup>, Allan
- 4 M Bennett<sup>1</sup>, Derek Morgan<sup>3</sup>, Neil Pearce<sup>6</sup>, Tony Fletcher<sup>7</sup>, Elizabeth B Brickley<sup>5b</sup> and
- 5 Yigun Chen<sup>5b</sup>.
- 6 Affiliated addresses: <sup>1</sup>Research and Evaluation, UK Health Security Agency,
- 7 Porton Down, Salisbury, United Kingdom; <sup>2</sup>Department of Non-communicable
- 8 Disease Epidemiology, London School of Hygiene & Tropical Medicine, London,
- 9 United Kingdom; <sup>3</sup>Health and Safety Executive, Science Division, Buxton, United
- 10 Kingdom; <sup>4</sup>Rapid Investigation Team, Field Services, UK Health Security Agency,
- 11 Wellington House, London, United Kingdom; <sup>5</sup>Department of Infectious Disease
- 12 Epidemiology, London School of Hygiene & Tropical Medicine, London, United
- Kingdom; <sup>6</sup>Department of Medical Statistics, London School of Hygiene & Tropical
- 14 Medicine, London, United Kingdom; <sup>7</sup>Chemical and Environmental Effects
- Department, UK Health Security Agency, Chilton, UK. aThese first authors
- contributed equally; <sup>b</sup>these senior authors contributed equally.
- 17 \*Corresponding author: Barry Atkinson (barry.atkinson@phe.gov.uk)
- 18 +44 (0)1980 616739
- 19 **Word Count:** Abstract 79; Main text 1516.
- 20 **Key words:** COVID-19; SARS-CoV-2; workplace outbreak; environmental sampling,
- 21 environmental assessment.

# **Abstract**

Between August-September 2021, an outbreak of SARS-CoV-2, with an attack rate of 55% (22/40 workers), occurred in a public-facing office in England. To identify workplace and worker-related risk factors, a comprehensive investigation involving surface sampling, environmental assessment, molecular and serological testing, and worker questionnaires was performed in September – October 2021. The results affirm the utility of surface sampling to identify SARS-CoV-2 control deficiencies and the importance of evolving, site-specific risk assessments with layered COVID-19 mitigation strategies.

#### **Outbreak Setting and Attack Rates**

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

The outbreak site was a three-storey public sector facility comprising three large open-plan offices, low-occupancy offices, meeting rooms, a canteen/lunchroom, and a small security office. Within the lower tier local authority area, the 7-day average SARS-CoV-2 incidence rate increased from 34/100,000 in mid-June to around 300/100,000 from late July onwards, and ranged between 268 and 331 weekly cases per 100,000 population during the outbreak period (Figure 1). Seventy-eight percent of local residents (aged ≥12 years) had received two doses of COVID-19 vaccines prior to the outbreak. The workplace had a site specific COVID-19 prevention strategy in place based on a generic template provided by the parent organisation. Control measures included COVID-19 training for workers, single occupancy desks with 2m spacing, plastic dividers between workers and the public, commercial hand sanitizers, and a cleaning regimen including in between appointments with members of the public. Ventilation on site was predominately natural (i.e. manually opened windows) with some locally controlled air conditioning units and limited forced mechanical general ventilation. The 40 workers included four (10.0%) cleaners, 30 (75.0%) office-based staff who had up to 15 face-to-face meetings with visitors per day, and six (15.0%) security staff who patrolled the facility on 30-minute rotating shifts, booked-in visitors, and operated shared equipment in a 7.8m<sup>2</sup> office. The overall attack rate of SARS-CoV-2 was 55%, with 75% of cleaners (3/4), 47% of office staff (14/30), and 67% of security staff (4/6) testing positive. Between end of August and mid-September 2021, a 'circuit break' closure was implemented to stop transmission within the workplace.

## **COVID-OUT Outbreak Investigation**

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Following notification, a comprehensive investigation by the COVID-19 Outbreak Investigation to Understand Transmission (COVID-OUT) study team, part of the PROTECT COVID-19 National Core Study on transmission and environment [1], was conducted in September and October 2021, using the previously described protocol [2]. Two rounds of surface sampling were performed using either Envirostik with Neutralising Buffer (Technical Service Consultants Ltd) or UTM® Viral Transport swabs (Copan) as appropriate. The first round of sampling was during the circuit break; the second round approximately two weeks later the site reopened. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for both ORF1ab and nucleocapsid (N) gene targets was performed in duplicate using the VIASURE SARS-CoV-2 Real Time PCR Detection Kit (CerTest) in accordance with the manufacturer's instructions. Out of 60 surfaces tested in the first round of sampling approximately 1-week after the first identified case, 10 (16.7%) were confirmed positives, and one (1.7%) was a suspected positive (Table 1). Five (8.3%) positive samples produced crossing threshold (Ct) values between 32.0-34.9; whole genome sequencing was attempted on these five samples, but only partial sequence was identified from a single sample (window handle). The data generated implied delta variant sequence but as <50% of the genome was recovered this could not be confirmed. The security office appeared to be a site of enhanced contamination, with six of nine (66.7%) samples from this location testing positive including three in the 32.0-34.9 Ct bracket. Based on these findings, enhanced cleaning was performed prior to the site re-opening, and routine cleaning procedures were updated to include window handle disinfection; maximum occupancy and cleaning regimens in the confined security office were also

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

reassessed. Repeat surface sampling performed approximately 1-week after reopening identified only one positive (2.4%) and one suspected positive (2.4%) sample, both near the assay's limit of detection. Ventilation was assessed using CO<sub>2</sub> as a proxy; concentrations were determined by spot measurements when the facility re-opened, with continuous measurements logged over the subsequent two-week period in selected locations. These indicated that, although largely by natural means, ventilation conformed with current guidance [3], including in the security office where CO<sub>2</sub> levels did not exceed 1200ppm and typically were <700ppm. At the time of the outbreak, the maximum occupancy of this office was two with security staff rotating positions regularly between this location and other areas within the building. Both occupancy levels for this office and security staff rotation patterns were modified upon reopening based on the findings of this study. 12 workers (100% office workers on regular day shift; 75% permanent contract) consented to participate in the COVID-OUT study, which included completing online questionnaires [4], two rounds of SARS-CoV-2 antibody testing, and three rounds of self-administered nose and throat swabs for qRT-PCR testing [2]. Of the 12 participants, five (41.7%) self-reported positive SARS-CoV-2 tests during the outbreak period: COVID-OUT serological testing confirmed all five were positive for both N- and S-specific antibodies against SARS-CoV-2 and two were positive by qRT-PCR. The non-cases were positive for S- but not N- antibodies, confirming that they had been vaccinated but not previously infected (Table 2). Prior to the outbreak, all participants, including the five cases, had received two doses of COVID-19 vaccines (date range of second dose: early May to mid-July in testpositives (cases) and mid-May to late July in non-cases; n=2 (18%) with

Pfizer/BioNTech and n=9 (82%) with Oxford/AstraZeneca). All five cases were symptomatic for COVID-19 and presented with at least one of the following symptoms: fever, dry cough, productive cough, shortness of breath, and/or loss of taste or smell. Contact patterns were similar between cases and non-cases: roughly half reported >6 close contacts (i.e., during work, social, and essential activities) per day on average over the prior 14 days. Two-thirds of participants reported using face masks both at work and outside of work with a higher proportion of non-cases using face masks nearly all the time. Four participants (33%; two cases and two non-cases) reported direct physical or close contact with co-workers and members of the public. Of these, one worker (25%) reported a divider/screen between colleagues and three (75%) reported a divider/screen between themselves and members of the public. One participant reported no screen between themselves and colleagues or the public and reported that they could 'sometimes' maintain social distance with colleagues and 'rarely' with the public.

## Discussion

In late August-September 2021, a public-facing office in England, with adherence to governmental COVID-19 control guidance and high vaccination coverage, experienced an outbreak of SARS-CoV-2 affecting 55% of the workforce. At the time of this outbreak, governmental guidance for workplaces in England prioritized policies for risk assessments, adequate ventilation, frequent cleaning, self-isolation, and communication/training; however, social distancing and face covering usage were no longer compulsory. Two weeks before the outbreak, government guidance was amended so fully vaccinated people did not need to self-isolate if they were identified as a close contact of someone with COVID-19.

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

Despite existing COVID-19 control measures, surface sampling identified potential deficiencies in routine disinfection procedures that informed targeted strengthening of infection control practices to support workplace re-opening. Similar to other SARS-CoV-2 outbreak studies, relatively low-level contamination was identified even in locations associated with recent occupancy of symptomatic people [5–10]. No positive surface sample yielded complete genome sequence suggesting degradation of the viral genome and a lack of transmission potential at the time of sampling. Similar investigations imply Ct values of <30 correlate with presence of infectious virus [11]. While vaccines remain highly effective for preventing severe COVID-19 illness and death, SARS-CoV-2 infections among fully vaccinated individuals in this outbreak are consistent with previous reports [12] and reinforce the importance of a layered SARS-CoV-2 transmission mitigation strategy prioritising ventilation and risk assessment-informed interventions, such as testing, social distancing, appropriate occupancy levels and transmission control measures (e.g. face masks), in addition to vaccination. Overall, our findings highlight the need for evolving, site-specific risk assessments that adapt for changes in local community infection rates and recognize heterogeneity within a workplace in the risks associated with different workspaces (e.g. rooms with high occupancy) and worker roles (e.g. desk-based versus circulating staff). For public-facing workplaces, these assessments must inform suitable control measures to minimize potential close interactions of staff members with co-workers and visitors.

The limitations of this study warrant consideration. Surface sampling and participant testing performed closer to the peak of cases could yield a more representative indication of contamination within the facility and facilitate more informative genomic sequencing and epidemiological assessment [13]. Although workplace transmission appears likely, given the clustering of cases in some areas and positive environmental sampling, we were unable to clarify chains of transmission and determine whether cases may have been independently introduced from community sources. Notably, the worker participation rate in COVID-OUT was 30%, with an underrepresentation of male workers as well as cleaning and security staff. The small sample size and potential for selection bias limit our ability to evaluate individual risk factors within the workplace. The ability to rapidly investigate SARS-CoV-2 outbreaks in workplaces and implement data-informed SARS-CoV-2 transmission mitigation measures is of importance for maintaining core societal functions during the COVID-19 pandemic. This is particularly relevant to workplaces with public-facing elements that have a dynamic population with an elevated risk of virus introduction and onward transmission. Mechanisms to encourage workplaces to report potential outbreaks as early as practicable and engage with research studies, like the one presented here, should be prioritized to further our understanding of transmission and to provide safer work environments.

### Copyright

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

© Crown copyright (2021), Health and Safety Executive. This is an open access article distributed under the terms of the Open Government Licence v3.0, which

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

permits re-use, distribution, reproduction and adaptation, provided the original work is properly cited. Acknowledgments The authors wish to acknowledge Antony Spencer, Vince Sandys, Joan Cooke, Gary Dobbin, Hannah Higgins, Chris Keen, Alice Graham and Helen Collins for their efforts in recruitment and data collection supporting the COVID-OUT project, and for assisting with this investigation. The authors further acknowledge the assistance of the UKHSA Genomic Team for sequencing samples of interest from this study. **Declarations** Financial support: This work was supported by funding from the PROTECT COVID-19 National Core Study on Transmission and Environment, managed by the Health and Safety Executive on behalf of HM Government. Conflict of interest: None declared. Ethical approval: The COVID-OUT study has been approved by the NHS North East Research Ethics Committee (Reference 20/NE/0282). Data availability statement: The data that support the findings of this study are presented in this report. Additional data relating to the wider COVID-OUT project will be published and catalogued within the NCS PROTECT repository available at https://sites.manchester.ac.uk/covid19-national-project/. **Authors' contributions:** Barry Atkinson: Conceptualisation, methodology, validation, formal analysis, investigation, data curation, writing - original draft, writing - review and editing, and supervision.

- 199 Karin van Veldhoven: Conceptualisation, methodology, validation, formal analysis,
- 200 data curation, writing original draft, writing review and editing.
- 201 Ian Nicholls: Validation, formal analysis, investigation, data curation, writing -
- 202 review and editing.
- 203 Matthew Coldwell: Conceptualisation, methodology, validation, formal analysis,
- 204 investigation, data curation, writing original draft, writing review and editing,
- 205 supervision.
- 206 Adam Clarke: Validation, formal analysis, investigation, data curation, writing -
- review and editing.
- 208 Gillian Frost: Validation, data curation, writing original draft, writing review and
- 209 editing.
- 210 **Christina J. Atchison:** Methodology, writing review and editing.
- 211 **Amber I. Raja:** Methodology, writing original draft, writing review and editing.
- 212 Allan M Bennett: Conceptualisation, methodology, validation, writing original draft,
- 213 writing review and editing, supervision, project administration and funding
- 214 acquisition.
- 215 Derek Morgan: Conceptualisation, methodology, writing review and editing,
- supervision, project administration and funding acquisition.
- 217 **Neil Pearce:** Conceptualisation, methodology, writing review and editing, project
- 218 administration and funding acquisition.
- 219 **Tony Fletcher:** Conceptualisation, methodology, writing review and editing.
- 220 Elizabeth B Brickley: Conceptualisation, methodology, writing original draft,
- 221 writing review and editing, and supervision.

- 222 **Yiqun Chen:** Conceptualisation, methodology, validation, investigation, data
- curation writing original draft, writing review and editing, supervision, and project
- 224 administration.

229

#### Disclosure Statement

- The contents of this paper, including any opinions and/or conclusions expressed, are
- 227 those of the authors alone and do not necessarily reflect Health and Safety
- 228 Executive or UK Health Security Agency policy.

#### References

- 1. PROTECT COVID-19 National Core Study. The PROTECT COVID-19 National
- 231 Core Study on transmission and environment.
- 2021(https://sites.manchester.ac.uk/covid19-national-project/). Accessed 6
- 233 November 2021.
- 234 2. Chen Y, et al. The COVID-OUT study protocol: COVID-19 outbreak investigation
- to understand workplace SARS-CoV-2 transmission in the United Kingdom.
- Wellcome Open Research, 2021 Aug. Report No.: 6:201.
- 237 3. Chartered Institution of Building Services Engineers. COVID-19: Ventilation.
- 238 COVID-19: Ventilation. 2021(https://go.cibse.org/l/698403/2021-07-
- 239 16/58mxjt/698403/1626442809vU1W2onF/COVID\_19\_\_\_Ventilation\_v5.pdf).
- Accessed 6 November 2021.
- 4. Chen Y, et al. COVID-19 risk questionnaire for workers COVID-OUT study.
- 242 OSF OSF, 2021; Published online: 13 May 2021.doi:10.17605/OSF.IO/W8ZV5.
- 5. Rooij MMT de, et al. Potential environmental transmission routes of SARS-CoV-
- 244 2 inside a large meat processing plant experiencing COVID-19 clusters. *medRxiv*
- 245 Cold Spring Harbor Laboratory Press, 2021; : 2021.06.20.21259212.
- 6. **Gholipour S, et al.** Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
- 247 CoV-2) Contamination of High-touch Surfaces in Field Settings. *Biomedical and*
- 248 environmental sciences: BES 2020; **33**: 925–929.
- 7. **Marshall DL, et al.** Sentinel Coronavirus environmental monitoring can
- contribute to detecting asymptomatic SARS-CoV-2 virus spreaders and can
- verify effectiveness of workplace COVID-19 controls. *Microbial Risk Analysis*
- 252 2020; **16**: 100137.
- 8. **Mouchtouri VA**, *et al.* Environmental contamination of SARS-CoV-2 on
- surfaces, air-conditioner and ventilation systems. *International Journal of*
- 255 Hygiene and Environmental Health 2020; **230**: 113599.

256 9. Marcenac P, et al. Detection of SARS-CoV-2 on Surfaces in Households of Persons with COVID-19. International Journal of Environmental Research and 257 Public Health 2021; 18 Published online: 2 August 258 259 2021.doi:10.3390/ijerph18158184. 260 Cherrie JW, et al. Contamination of Air and Surfaces in Workplaces with SARS-CoV-2 Virus: A Systematic Review. Annals of Work Exposures and Health 261 Oxford Academic, 2021; 65: 879-892. 262 263 11. Zhou J, et al. Investigating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare Setting 264 265 During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in London. Clinical Infectious Diseases: An Official Publication of the Infectious 266 Diseases Society of America 2021; 73: e1870–e1877. 267 12. Brown CM. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine 268 269 Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. MMWR. Morbidity and Mortality Weekly 270 Report 2021; **70**Published online: 2021.doi:10.15585/mmwr.mm7031e2. 271 13. Bart SM, et al. Multiple Transmission Chains within COVID-19 Cluster, 272 Connecticut, USA, 2020 - Volume 27, Number 10—October 2021 - Emerging 273 Infectious Diseases journal - CDC. Published online: 274 275 doi:10.3201/eid2710.211196. 276

# Table 1: Data collected from two rounds of surface sampling in the COVID-OUT investigation of an outbreak of SARS-CoV-2 in an office-based workplace, England, August to September 2021.

Site sampling of	data								
		qRT-PCR result			qRT-PCR Mean Ct grouping				
Time of sampling	Samples collected	Positive n (%)	Suspected n (%)	Negative n (%)	Ct <32.0 n (%)	Ct 32.0- 34.9 n (%)	Ct >35.0 <sup>a</sup> n (%)		
Circuit-break	60	10 (16.7%)	1 (1.7%)	49 (81.7%)	0 (0.0%)	5 (8.3%)	55 (91.7%)		
Reopening	42	1 (2.4%)	1 (2.4%)	40 (95.2%)	0 (0.0%)	0 (0.0%)	42 (100%)		
Positive sampl	e information	n							
	Location Time of sampling		Description		Mean Ct Value <sup>b</sup>		Estimated copies per cm <sup>2c</sup>		
floor) Circuit-bi	Open plan office (2 <sup>nd</sup> floor) Circuit-break		Window handle		33.6		4,589.9		
Meeting room Circuit-break			Air vent		37.6 (suspect <sup>d</sup> )		25.1		
Meeting room Circuit-break		Desk + chair		37.4		7.0			
Canteen Circuit-break		Table + chair		34.2		35.2			
Security office Circuit-break		Radio (two-way)		36.7		12.8			
Security office Circuit-break		Telephone		34.6		583.1			
Security office Circuit-break		Key press		34.5		148.1			
Security office Circuit-break		Control panel		34.2		229.4			
Security office Circuit-break		Telephone		35.1		214.2			
Security office Circuit-break		Desk + chair		37.7		19.5			
Open plan office (ground floor) Circuit-break		Air conditioning unit		37.6		13.1			
Canteen Reopening		Desk + chair		37.6 (suspect <sup>d</sup> )		1.1			
Canteen Reopening		Desk + chair 3		37.2		1.7			

<sup>a</sup>Includes samples with no SARS-CoV-2 RNA detected. <sup>b</sup>Mean Ct value for the N gene. <sup>c</sup>Extrapolation from copies per reaction to copies per sample collected based on the dilution factor, then divided by recorded sampling area. <sup>d</sup>A 'suspected positive' is one where only a single replicate is positive in at least one target.

Table 2. Test results, clinical presentation, and characteristics of participants in the COVID-OUT investigation of an outbreak of SARS-CoV-2 in an office-based workplace, England, August to September 2021.

September 202		=		ases <sup>a</sup>		i-cases <sup>b</sup>		Total
0400 0 110	D. W. DT DCC		<u>n</u> 5	%	n	%	n	%
SARS-CoV-2				100.0	0	0.0	5	41.7
Testing	Self-reported positive test with	N-specific antibodies	5	100.0	0	0.0	5	41.7
Signs &	None reported		3	0.0	7	100.0	7	58.3
symptoms of	Fever			60.0	0	0.0	3	25.0
COVID-19	Dry cough			60.0	0	0.0	3	25.0
	Productive cough	3	60.0	0	0.0	3	25.0	
	Shortness of breath	3	60.0	0	0.0	3	25.0	
	Loss of taste		4	80.0	0	0.0	4	33.3
Vaccines	Pfizer/BioNTech, two doses	0	0.0	2	28.6	2	16.7	
	Oxford/AstraZeneca, two doses	4	80.0	5	71.4	9	75.0	
	Missing		3	20.0	0	0.0	1	8.3
Direct physical	No			60.0	5	71.4	8	66.7
or close	Yes, with co-workers		0	0.0	0	0.0	0	0.0
contact with	Yes, with members of the public			0.0	0	0.0	0	0.0
co-workers or	Yes, with co-workers and mem	bers of the public	2	40.0	2	28.6	4	33.3
public	Missing		0	0.0	0	0.0	0	0.0
COVID-19	Hand washing	Never	0	0.0	0	0.0	0	0.0
control measures at		1-10 times	1	20.0	1	14.3	2	16.7
		11+ times	4	80.0	5	71.4	9	75.0
work		Missing	0	0.0	1	14.3	1	8.3
	Wear any type of face mask <sup>c</sup>	Never	2	40.0	0	0.0	2	16.7
	, ,,	< half the time	0	0.0	0	0.0	0	0.0
		> half the time	0	0,0	2	28.6	2	16.7
		Nearly all the time	3	60.0	5	71.4	8	66.7
		Missing	0	0.0	0	0.0	0	0.0
	Wear gloves	Never	5	100.0	4	57.1	9	75.0
	3	< half the time	0	0.0	2	28.6	2	16.7
		> half the time	0	0.0	0	0.0	0	0.0
		Nearly all the time	0	0.0	1	14.3	1	8.3
		Missing	0	0.0	0	0.0	0	0.0
	Divider, colleagues	No	1	20.0	2	28.6	3	25.0
	Divider, concagues	Yes	1	20.0	0	0.0	1	8.3
		Not applicable <sup>d</sup>	3	60.0	5	71.4	8	66.7
		Missing	0	0.0	0	0.0	0	0.0
	Divider, public	No	0	0.0	1	14.3	1	8.3
	Divider, public	Yes	2	40.0	1	14.3	3	25.0
		Not applicable <sup>d</sup>	3	60.0	5	71.4	<u></u>	66.7
		Missing	0	0.0	0	0.0	0	0.0
	Social distancing colleggues	Rarely able to maintain	0	0.0	0	0.0	0	0.0
	Social distancing, colleagues	Sometimes able to	0	0.0	1	14.3	1	8.3
		maintain	U	0.0	ı	14.3	ı	0.3
			2	40.0	4	112	2	25.0
		Mostly able to maintain		40.0	1	14.3	3	25.0
		Always able to maintain	0	0.0	0	0.0	0	0.0
	Conial distancian multi-	Missing	3	60.0	5	71.4	8	66.7
	Social distancing, public	Rarely able to maintain	0	0.0	1	14.3	1	8.3
		Sometimes able to	1	20.0	0	0.0	1	8.3
		maintain	-	00.0		05.7	40	00.0
		Mostly able to maintain	4	80.0	6	85.7	10	83.3
		Always able to maintain	0	0.0	0	0.0	0	0.0
		Missing	0	0.0	0	0.0	0	0.0
COVID-19	Wear any type of face mask <sup>c</sup>	Never	0	0.0	0	0.0	0	0.0
		< half the time	1	20.0	0	0.0	1	8.3
		> half the time	1	20.0	1	14.3	2	16.7
measures not		· · · · · · · · · · · · · · · · · · ·						
measures not		Nearly all the time	2	40.0	6	85.7	8	66.7
measures not		· · · · · · · · · · · · · · · · · · ·						66.7 8.3
control measures not at work  Number of close contacts	Household	Nearly all the time	2	40.0	6	85.7	8	

		3-5	0	0.0	5	71.4	5	41.7
		Missing	0	0.0	0	0.0	0	0.0
	Work	None	2	40.0	1	14.3	3	25.0
		1-2	0	0.0	2	28.6	2	16.7
		3-5	0	0.0	0	0.0	0	0.0
		6-20	2	40.0	2	28.6	4	33.3
		21-100	0	0.0	2	28.6	2	16.7
		Missing	1	20.0	0	0.0	1	8.3
	Commute	None	4	80.0	6	85.7	10	83.3
		1-2	0	0.0	1	14.3	1	8.3
		Missing	1	20.0	0	0.0	1	8.3
	Social	None	2	40.0	1	14.3	3	25.0
		1-2	0	0.0	0	0.0	0	0.0
		3-5	1	20.0	1	14.3	2	16.7
		6-20	2	40.0	3	42.9	5	41.7
		21-100	0	0.0	1	14.3	1	8.3
		Missing	0	0.0	1	14.3	1	8.3
	Essential	None	1	20.0	1	14.3	2	16.7
		1-2	1	20.0	1	14.3	2	16.7
		3-5	1	20.0	0	0.0	1	8.3
		6-20	1	20.0	1	14.3	2	16.7
		21-100	0	0.0	4	57.1	4	33.3
		Missing	1	20.0	0	0.0	1	8.3
ong close	Non-household	Never	3	60.0	2	28.6	5	41.7
contacts (>1h		<1/day	0	0.0	3	42.9	3	25.0
n same space)		1/day	0	0.0	2	28.6	2	16.7
,		>1/day	2	40.0	0	0.0	1	8.3
		Missing	0	0.0	0	0.0	0	0.0
	Work	Never	3	60.0	4	57.1	7	58.3
	Work	<1/day	0	0.0	2	28.6	2	16.7
		1/day	1	20.0	0	0.0	1	8.3
		>1/day	<u>.</u> 1	20.0	1	14.3	2	16.7
		Missing	0	0.0	0	0.0	0	0.0
	Commute	Never	5	100.0	6	85.7	11	91.7
	Commute	<1/day	0	0.0	1	14.3	1	8.3
		Missing	0	0.0	0	0.0	0	0.0
	Social	Never	3	60.0	3	42.9	6	50.0
	Social	<1/day	<u></u>	20.0	3	42.9	4	33.3
		1/day	1	20.0	0	0.0	1	8.3
		Missing	0	0.0	1	14.3	1	8.3
	Essential	Never	2	40.0	3	42.9	5	41.7
	E22GIIIGI							
		<1/day	2	40.0	2	28.6	4	33.3
22		1/day	0	0.0	0	0.0	0	0.0
		>1/day	0	0.0	2	28.6	2	16.7
		Missing	1	20.0	0	0.0	1	8.3

<sup>a</sup>Confirmed cases were defined as participants who presented during the outbreak period with: (i) RT-PCR evidence of a SARS-CoV-2 infection, (ii) N-specific seroconversion, or (iii) self-reporting of a positive test (i.e., by RT-PCR or LFD) with positive N antibody results. Suspected cases were defined as participants who presented during the outbreak period with no positive RT-PCR or N antibody results in COVID-OUT testing but with: (i) self-reporting of a positive test (i.e., by RT-PCR or LFD) or (ii) symptoms consistent with COVID-19 defined as: (a) acute onset of fever (>37.8C) and new continuous cough or (b) acute onset of any three or more of fever (>37.8C), cough, shortness of breath, loss of taste or smell, runny nose, fatigue, sore throat, muscle or body aches, headache, nausea or vomiting, and/or diarrhoea. Only confirmed cases were identified. <sup>b</sup>Two out of seven controls did not undertake any testing as part of COVID-OUT and so are not confirmed negatives but classified as non-cases. <sup>c</sup>Includes washable, surgical, disposable, FFP2 and FFP3. <sup>d</sup>Not applicable: participants did not report direct physical or close contract with co-workers or members of the public. <sup>e</sup>Close Contact' defined as: typically spending more than 15 minutes within 2 metres of someone

Abbreviations: RT-PCR: real-time polymerase chain reaction.

Figure 1: Timeline of the COVID-OUT investigation in a public-facing office, England, June to November 2021. Cases were identified between end of August and mid-September. Text/Arrows indicates key dates of the COVID-OUT study activities. The circuit-break, which was implemented at the moment of identification of the initial cluster of cases, lasted 2 weeks. The line chart represents the 7-day average case rate for the lower tier local authority area at which the company is based (publicly available from (https://coronavirus.data.gov.uk/); date of download 9 November 2021.

